VeriSIM Life announces recognition for continued advances with BIOiSIM, a first-in-class virtual drug development engine.
VeriSIM Life— the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development— announced that it has once again been named “Predictive Analytics Solution of the Year” at the 2023 BioTech Breakthrough Awards. The company was first recognized in the same category in 2022. The awards program, now in its third year, is conducted by BioTech Breakthrough, a leading independent marketing intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
VeriSIM was recognized for continued advances with the company’s virtual drug development engine, BIOiSIM, a platform that combines artificial intelligence and machine learning with biosimulation to make early and accurate predictions about the safety and efficacy of compounds used in drug development. The use of BIOiSIM is proven to decrease the risk of errors and failures in the drug development process and de-risk clinical trials and early patient applications by predicting outcomes before treatments are given. Ultimately, BIOiSIM helps to accelerate pathways to market for novel therapeutics, positively impacting the lives of patients for whom these treatments may otherwise never have been available.
“It is an honor to be recognized for our innovations in predictive analytics for drug development for a second consecutive year,” said Dr. Jo Varhsney, Founder and CEO of VeriSIM Life. “This award highlights the ongoing positive changes that VeriSIM and BIOiSIM are making in the life sciences industry and drug development pipeline that will make a positive difference for doctors and their patients.”
Also Read: Bayer and Recursion focus research collaboration on Oncology
Earlier this year, VeriSIM announced a new partnership with Clarivate— a leading global information services provider, to further expand the company’s capabilities in accelerating and de-risking drug development. Working together, VeriSIM and Clarivate have now released a new Translational Index Dashboard product for customers to accelerate early scientific investigation powered by Clarivate data and VeriSIM Life’s AI platform.
Recently, the company also conducted a client collaboration focused on optimizing treatments for substance use disorders by improving the accuracy of predictions for drug partitioning into brain tissue crossing the blood brain barrier. Using BIOiSIM, the team demonstrated prediction accuracy exceeding the industry standard threshold for reliability and identified ~20,000 molecules capable of blood brain barrier permeability and disposition into the brain.
“Our ever-growing number of client collaborations and partnerships is indicative of an industry-wide desire for positive changes and acceleration in the drug development pipeline,” said Varshney. “We’re proud to be a part of a community that is willing to work together to improve what we’re all doing in order to achieve better patient outcomes.”
VeriSIM‘s work is being honored alongside other major breakthroughs in life sciences and biotechnology from ThermoFisher, Acumen Pharmaceuticals, Colossal Biosciences, Guardant Health, Mission Bio, Travere Therapeutics, Vaxess Technologies, Waters, and more.
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the top technology companies, solutions, and products in the life sciences and biotechnology industry today. This year’s program attracted thousands of nominations coming in from all over the world.
SOURCE: PRWeb
